The use of weighted Z-tests in medical research

Journal of Biopharmaceutical Statistics

Volumn 15, Issue 4, 2005, Pages 625-639

  Lan, K K Gordon ^a   Soo, Yuhwen ^a   Siu, Cynthia ^b   Wang, Mey ^c  

^a SANOFI   (France)

^b Data Power DP Inc   (United States)

^c Center for Drug Evaluation   (Taiwan)

Author keywords

Adapted design; Bridging study; Interim analysis; Sample size re estimation; Type I error; Weighted Z test

Indexed keywords

ARTICLE; DATA ANALYSIS; MATHEMATICAL ANALYSIS; MEDICAL RESEARCH; PRIORITY JOURNAL; PROCESS DESIGN; STANDARD; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; WEIGHTED Z TEST;

ALGORITHMS; BAYES THEOREM; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY; RESEARCH DESIGN; SAMPLE SIZE;

EID: 22044458425     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-200062284     Document Type: Article

References (25)

1. The Cardiac Arrhythmia Suppression Trial. (1989). Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 312:406-412.
2. The Cardiac Arrhythmia Suppression Trial II Investigators. (1992). Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New England Journal of Medicine 327:227-233.
3. Chen, Y. H. J., DeMets, D. L., Lan, K. K. G. (2004). Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 23:1023-1038.
4. Chow, S. C., Shao, J., Hu, O. Y. P. (2002). Assessing sensitivity and similarity in bridging studies. Journal of Biopharmaceutical Statistics 12:385-400.
5. Cui, L., Hung, H. M. J., Wang, S. J. (1999). Modification of sample size in group sequential clinical trials. Biometrics 55:853-857.
6. Echt, D. S., Liebson, P. R., Mitchell, L. B. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac Arrhythmia suppression trial. New England Journal of Medicine 324:781-788.
7. Fisher, L. D. (1998). Self-designing clinical trials. Statistics in Medicine 17:1551-1562.
8. Hung, H. M. J., Cui, L., Wang, S. J., Lawrence, J. (2002). Adaptive statistical inference following sample size modification based on interim review of effect size. American Statistical Association Proceedings of the Joint Statistical Meetings 1542-1548.
9. Hung, H. M. J., Cui, L., Wang, S. J., Lawrence, J. (2005). Adaptive statistical analysis following sample size modification based on interim review of effect size. Journal of Biopharmaceutical Statistics 15:693-706.
10. International Conference on Harmonization. (1998). Tri-partite guidance E5 ethnic factors in the acceptability of foreign data. Federal Register 83:31790-31796.
11. Lan, K. K. G. (2003). Adaptive designs in clinical trials. International Chinese Statistical Association Bulletin 46-47.
12. Lan, K. K. G., Wittes, J. (1988). The B-value: A tool for monitoring data. Biometrics 44:579-585.
13. Lan, K. K. G., Zucker, D. M. (1993). Sequential monitoring of clinical trials: The role of information and Brownian motion. Statistics in Medicine 12:753-765.
14. Lan, K. K. G., Trost, D. C. (1997). Estimation of parameters and sample size re-estimation. American Statistical Association Proceedings of the Biopharmaceutical Section 48-51.
15. Lawrence, J., Hung, H. M. J. (2003). Estimation and confidence intervals after adjusting the maximum information. Biometrical Journal 45:143-152.
16. Liu, J. P. (2003). Comparison of statistical methods for evaluating bridging studies. Drug Information Journal Supplement 37:87-97.
17. Liu, Q., Proschan, M. A., Pledger, G. W. (2002). A unified theory of two-stage adaptive designs. Journal of American Statistical Association 97:1034-1041.
18. Proschan, M. A., Liu, Q., Hunsberger, S. (2003). Practical midcourse sample size modification in clinical trials. Controlled Clinical Trials 24:4-15.
19. Shen, Y., Fisher, L. D. (1999). Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55:190-197.
20. Shih, W. J. (2001). Clinical trials for drug registration in Asian-Pacific countries: Proposal for a new paradigm from a statistical perspective. Controlled Clinical Trials 22:357-366.
21. Siu, C. O., Lan, K. K. G. (2001). Flexible interim analysis method for sample size re-estimation and early stopping: A conditional power approach. American Statistical Association Proceedings of the Joint Statistical Meetings 5-9.
22. Wang, C., Keller, D. S., Lan, K. K. G. (2002). Sample size re-estimation for binary data via conditional power. American Statistical Association Proceedings of the Joint Statistical Meetings 3621-3626.
23. Ware, J., Wei, L. J., Hughes, M., Morris, C. (2002). Bridging and global drug development: A regional strategy. Presented in the Joint Statistical Meetings 2002.
24. Wei, L. J., Durham, S. (1978). The randomized play-the-winner rule. Journal of the American Statistical Association 73:840-843.
25. Wittes, J., Brittain, E. (1990). The role of internal pilot studies in increasing the efficiency of clinical trials. Statistics in Medicine 9:65-12.